Recommendations for the management of postmenopausal vaginal atrophy.
نویسندگان
چکیده
Unlike hot flushes and night sweats which resolve spontaneously in time, atrophic symptoms affecting the vagina and lower urinary tract are often progressive and frequently require treatment. The prevalence of vaginal dryness increases as a woman advances through the postmenopausal years, causing itching, burning and dyspareunia, and sexual activity is often compromised. But, despite the various safe and effective options, only a minority (about 25% in the Western world and probably considerably less in other areas) will seek medical help. Some of this reluctance is due to the adverse publicity for hormone replacement therapy (HRT) over recent years that has suggested an increased risk of breast cancer, heart disease and stroke. But, regardless of whether these scares are justified, local treatment of vaginal atrophy is not associated with these possible risks of systemic HRT. Other reasons for the continued suffering in silence may be cultural and an understandable reluctance to discuss such matters, particularly with a male doctor, but the medical profession must also take much of the blame for failing to enquire of all postmenopausal women about the possibility of vaginal atrophic symptoms. Vaginal dryness can be helped by simple lubricants but the best and most logical treatment for urogenital atrophy is to use local estrogen. This is safe, effective and with few contraindications. It is hoped that these guidelines and recommendations, produced to coincide with World Menopause Day 2010, will help to highlight this major cause of distress and reduced quality of life and will encourage women and their medical advisers all over the world to seek and provide help.
منابع مشابه
The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
OBJECTIVE To create an evidence-based position statement published by The North American Menopause Society (NAMS) on the role of local vaginal estrogen therapy (ET) for the treatment of vaginal atrophy in postmenopausal women. DESIGN NAMS followed the general principles established for evidence-based guidelines to create this document. A panel of clinicians and researchers acknowledged to be ...
متن کاملLasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Lasofoxifene is a selective estrogen receptor modulator (estrogen agonist/antagonist) that has completed phase III trials to evaluate safety and efficacy for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy in postmenopausal women. In postmenopausal women with low or normal bone mineral density (BMD), lasofoxifene increased BMD at the lumbar spine and hip an...
متن کاملPractical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women.
INTRODUCTION The decline in circulating estrogen levels in peri- and postmenopause has a wide range of physiological effects, including atrophy of tissues in the urogenital tract. Vaginal atrophy is an important contributor to postmenopausal sexual dysfunction. AIM To provide a framework for clinical evaluation and clinical management of sexual dysfunction secondary to vaginal atrophy. METH...
متن کاملEffects of Phytoestrogens in Alleviating the Menopausal Symptoms: A Systematic Review and Meta-Analysis
The aim of this research was to perform a systematic review of the efficacy of non-hormonal herbal drugs in the treatment of vaginal atrophy in postmenopausal women. Three electronic databases were systematically searched from their inception to May2015: PubMed, Cochrane Library (Cochrane Central Register of Controlled Trials) and Scopus. In this meta-analysis, vaginal maturation value was cons...
متن کاملEffects of Phytoestrogens in Alleviating the Menopausal Symptoms: A Systematic Review and Meta-Analysis
The aim of this research was to perform a systematic review of the efficacy of non-hormonal herbal drugs in the treatment of vaginal atrophy in postmenopausal women. Three electronic databases were systematically searched from their inception to May2015: PubMed, Cochrane Library (Cochrane Central Register of Controlled Trials) and Scopus. In this meta-analysis, vaginal maturation value was cons...
متن کاملReviewing the options for local estrogen treatment of vaginal atrophy
BACKGROUND Vaginal atrophy is a chronic condition with symptoms that include vaginal dryness, pain during sex, itching, irritation, burning, and discharge, as well as various urinary problems. Up to 45% of postmenopausal women may be affected, but it often remains underreported and undertreated. This article aims to review the current recommendations for treatment of vaginal atrophy, and curren...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Climacteric : the journal of the International Menopause Society
دوره 13 6 شماره
صفحات -
تاریخ انتشار 2010